Skip to main content
logo
Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
2.775
-0.025 (-0.89%)
Aug 10, 2026, 10:44 AM EDT - Market open

Fate Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
6.326.6513.6363.5396.355.85
Revenue Growth
-52.64%-51.24%-78.55%-34.03%72.44%77.66%
Gross Profit
6.326.6513.6363.5396.355.85
Operating Income
-139.42-147.7-210.28-190.51-308.39-216.99
Net Income
-129.91-136.32-186.26-160.93-281.72-212.15
Earnings Per Share
-1.09-1.15-1.64-1.64-2.91-2.24
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
174.82203.66279.07315.18436.23615.91
Total Debt
76.7977.8585.27103.54109.34114.82
Net Cash (Debt)
98.04125.81193.8211.64326.89501.09
Net Cash Growth
-37.59%-35.09%-8.43%-35.26%-34.77%29.95%
Net Cash Per Share
0.821.061.702.163.385.29

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-103.1-106.08-122.87-132.26-248.21-162.87
Capital Expenditures
-5-5.95-0.73-6.15-35.57-50.7
Free Cash Flow
-108.09-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingMar '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-2207.47%-2222.45%-1542.63%-299.86%-320.24%-388.56%
Pretax Margin
-2056.79%-2051.08%-1366.46%-253.30%-292.55%-379.89%
Profit Margin
-2056.79%-2051.08%-1366.46%-253.30%-292.55%-379.89%
FCF Margin
-1711.42%-1685.78%-906.79%-217.87%-294.68%-382.43%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
51.6719.0915.465.8110.19100.29